Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Mepolizumab in the treatment of severe asthma with nasal polyposis: real-life study

Sara Maria da Costa Martins, Eduarda Tinoco, Bruno Cabrita, Daniela Machado, Inês Franco, Inês Ladeira, Ivone Pascoal, Ricardo Lima, Salete Valente
European Respiratory Journal 2021 58: PA3727; DOI: 10.1183/13993003.congress-2021.PA3727
Sara Maria da Costa Martins
1Centro Hospitalar Universitário Cova da Beira, Covilhã, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sara.m.costamartins@gmail.com
Eduarda Tinoco
2Centro Hospitalar Vila Nova de Gaia/ Espinho, Vila Nova de Gaia, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruno Cabrita
3Hospital Pedro Hispano, Matosinhos, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Machado
2Centro Hospitalar Vila Nova de Gaia/ Espinho, Vila Nova de Gaia, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Inês Franco
2Centro Hospitalar Vila Nova de Gaia/ Espinho, Vila Nova de Gaia, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Inês Ladeira
2Centro Hospitalar Vila Nova de Gaia/ Espinho, Vila Nova de Gaia, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ivone Pascoal
2Centro Hospitalar Vila Nova de Gaia/ Espinho, Vila Nova de Gaia, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ricardo Lima
2Centro Hospitalar Vila Nova de Gaia/ Espinho, Vila Nova de Gaia, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Salete Valente
1Centro Hospitalar Universitário Cova da Beira, Covilhã, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Background: Nasal polyposis may impact asthma severity and is a frequent comorbidity in patients with severe eosinophilic asthma. Research has suggested mepolizumab may directly affect upper airway type 2 inflammatory conditions, however there is a lack of clinical studies confirming its effectiveness on nasal symptoms control.

Aims: To assess the impact of mepolizumab on nasal symptoms control in patients with severe eosinophilic asthma and nasal polyposis.

Methods: A multicenter retrospective study was performed in a cohort of patients with both nasal polyposis and severe refractory asthma treated with mepolizumab. Asthma-related parameters and sino-nasal clinical outcomes were analysed in baseline and 6-12 months after treatment initiation.

Results: Twelve patients were included with an average age of 59 years at the start of mepolizumab therapy. The participants were predominantly females (75%) and 58% had history of sinus surgery. After at least 6 months of treatment with mepolizumab, effective control of asthma-related clinical parameters was observed, with a reduction in moderate to severe exacerbations and systemic corticosteroid therapy. In parallel, there was also a statistically significant improvement of sino-nasal symptoms and quality of life, evidenced by a reduction in the average total score on the Sino-Nasal Outcome Test 22, from 70 to 28 points (p= 0.008), and Nasal Congestion scale (range of severe symptoms (3) to mild (1), (p= 0.010)).

Conclusions: Mepolizumab demonstrated clinical efficacy in controlling symptoms associated with nasal polyposis in patients with concomitant severe eosinophilic asthma, giving it the advantage of treating both conditions with the same intervention.

  • Treatments
  • Quality of life
  • Rhinitis

Footnotes

Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3727.

This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

  • Copyright ©the authors 2021
Previous
Back to top
Vol 58 Issue suppl 65 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Mepolizumab in the treatment of severe asthma with nasal polyposis: real-life study
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Mepolizumab in the treatment of severe asthma with nasal polyposis: real-life study
Sara Maria da Costa Martins, Eduarda Tinoco, Bruno Cabrita, Daniela Machado, Inês Franco, Inês Ladeira, Ivone Pascoal, Ricardo Lima, Salete Valente
European Respiratory Journal Sep 2021, 58 (suppl 65) PA3727; DOI: 10.1183/13993003.congress-2021.PA3727

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Mepolizumab in the treatment of severe asthma with nasal polyposis: real-life study
Sara Maria da Costa Martins, Eduarda Tinoco, Bruno Cabrita, Daniela Machado, Inês Franco, Inês Ladeira, Ivone Pascoal, Ricardo Lima, Salete Valente
European Respiratory Journal Sep 2021, 58 (suppl 65) PA3727; DOI: 10.1183/13993003.congress-2021.PA3727
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations
  • Late Breaking Abstract - First-time assessment of efficacy of candidate vaccine to prevent acute exacerbations of chronic obstructive pulmonary disease (AECOPD): multicentre, randomised, controlled, observer-blind phase 2b trial
  • Identifying super-responders to benralizumab in severe asthma
Show more Airway pharmacology and treatment

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society